Stocks · Healthcare · Biotechnology
Pelthos Therapeutics Inc. PTHS
$20.50 -0.49% Close, Oct 5, 2026 · AMEX · Market cap $71.6M
Weak trendExpensive vs sector
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 452.6% in a year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
- The stock is 45% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 26%
- Gross marginBottom 40%
- Operating marginBottom 27%
- Accruals (lower is better)Top 12%
- Interest coverBottom 36%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 2%
- Free-cash-flow yieldBottom 7%
- EBITDA / enterprise valueBottom 12%
- Sales / enterprise valueTop 36%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 32%
- 6-month returnBottom 26%
- 1-year return vs S&P 500Bottom 26%
- Distance from 52-week highBottom 33%
- Trend checklist (0–4)Bottom 13%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 23%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 31%
- Maximum drawdown, 3 yearsTop 25%
- Beta vs S&P 500 (lower is better)Bottom 18%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Gross margin | 54.7% | — | Bottom 40% | |
| Operating margin | -133.4% | — | Bottom 27% | |
| Net margin | -165.2% | — | — | |
| Free-cash-flow margin | -98.4% | — | — | |
| Return on invested capital | -49.4% | — | Bottom 26% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -21.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.0%
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -7.8×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -38.53%
- Shareholder yield
- -38.53%
- Share count change, 1 year
- +452.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jun 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- -1.9%
- Positive 20 days after report
- 2 of 5
Analysts
- Consensus price target
- $54.50
- Target vs current price
- +165.9%
- Analysts with a rating
- 3
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -134.8% | +0.1% | -10.7% | -22.4% | — |
| May 14, 2026 | +10.4% | +6.5% | +4.2% | +10.4% | +11.5% |
| Mar 19, 2026 | -73.9% | -4.6% | -8.3% | -4.5% | +14.2% |
| Nov 13, 2025 | -691.0% | -7.3% | -19.8% | -36.0% | -39.8% |
| Aug 13, 2025 | +7.6% | -4.3% | +7.9% | +63.2% | +94.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$6.62 | -$2.82 | -134.8% | $15.6M |
| May 14, 2026 | -$3.09 | -$3.45 | +10.4% | $10.9M |
| Mar 19, 2026 | -$6.87 | -$3.95 | -73.9% | $9.4M |
| Nov 13, 2025 | -$5.30 | -$0.67 | -691.0% | $7.4M |
| Aug 13, 2025 | -$5.38 | -$5.82 | +7.6% | — |
| May 13, 2025 | -$3.21 | -$2.90 | -10.7% | $150,000 |
| Mar 27, 2025 | -$3.23 | — | — | — |
| Nov 13, 2024 | -$2.90 | -$2.30 | -26.1% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2.77× | — | — | Top 36% |
| Free-cash-flow yield | -59.49% | — | — | Bottom 7% |
| Earnings yield | -204.54% | — | — | Bottom 2% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.4%
- 200-day average slope (20 days)
- -1.7%
- Distance from 50-day average
- -17.3%
- Distance from 200-day average
- -17.8%
- RSI (14)
- 36.5
- Relative volume
- 2.20×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 67.7%
- Volatility vs own 5-year history
- 19th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.85
- Correlation with S&P 500
- 0.30
- Current drawdown from 1-year high
- -45.2%
- Maximum drawdown, 3 years
- -51.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 6, 2025 | Feb 17, 2026 | -51.4% | 68 days | Not yet recovered |
| Jul 7, 2025 | Jul 9, 2025 | -36.5% | 2 days | 1 days (Jul 10, 2025) |
| Sep 23, 2025 | Oct 13, 2025 | -31.9% | 14 days | 8 days (Oct 23, 2025) |
| Jul 10, 2025 | Aug 13, 2025 | -31.3% | 24 days | 14 days (Sep 3, 2025) |
| Sep 4, 2025 | Sep 5, 2025 | -13.1% | 1 days | 5 days (Sep 12, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $71.6M
- EPS, diluted (TTM)
- -$41.93
- Revenue (TTM)
- $43.3M
- 52-week range
- $18.19 – $37.50
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $16.8M |
| Gross profit | $0 | $0 | $0 | $0 | $7.4M |
| Operating income | -$838,996 | -$2.3M | -$6.9M | -$7.6M | -$32.4M |
| Net income | -$595,387 | -$2.5M | -$7.4M | -$8.0M | -$43.3M |
| EPS (diluted) | -$1.00 | -$4.26 | -$12.80 | -$13.54 | -$23.04 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $7.4M | $9.4M | $10.9M | $15.6M |
| Net income | -$1.7M | -$1.9M | -$2.0M | -$3.4M | -$16.2M | -$21.7M | -$10.2M | -$23.4M |
| EPS (diluted) | -$2.90 | -$3.23 | -$3.20 | -$5.38 | -$25.35 | -$6.87 | -$3.09 | -$6.62 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Operating cash flow | -$1.6M | -$981,031 | -$5.8M | -$22.6M |
| Capital expenditure | $0 | $0 | $0 | -$99,000 |
| Free cash flow | -$1.6M | -$981,031 | -$5.8M | -$22.7M |
| Dividends paid | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $255,412 | $5.9M | $27.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $24.6M
- Total assets
- $137.4M
- Total liabilities
- $138.9M
- Total debt
- $73.1M
- Net debt
- $48.5M
- Shareholders’ equity
- -$1.5M
As of Jun 30, 2026 (filed Jun 30, 2026).
Short interest
- Shares sold short
- 93,741
- Days to cover
- 2.16
- Change vs previous report
- -10.1%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 2, 2025
- 1-for-10